Novavax Management

Mr. John Charles Jacobs, M.B.A., serves as President, Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023. He was Director of Life Sciences Pennsylvania from May 06, 2021 until Jan...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
James Kelly	Executive VP	1.8yrs	US$3.08m	0.0039% $ 24.2k
John Herrmann	Executive VP & Chief Legal Officer	11.2yrs	US$3.10m	0.017% $ 105.7k
Stanley Erck	Advisor	less than a year	US$8.40m	0.042% $ 263.1k
John Trizzino	Executive VP	1.8yrs	US$3.08m	0.011% $ 65.3k
John Jacobs	President	less than a year	no data	no data
Richard Crowley	Executive VP & COO	2.4yrs	no data	no data
Gale Smith	Senior VP of Discovery & Pre-Clinical Research and Chief Scientist	2.1yrs	US$489.25k	no data
Biegie Lee	Senior VP & Chief Information Officer	2.5yrs	no data	no data
Troy Morgan	Senior VP & Chief Compliance Officer	2.1yrs	no data	no data
Erika Trahan	Associate Director of Investor & Public Relations	5.1yrs	no data	no data
Sven Andreasson	Senior Vice President of Corporate Development	8.9yrs	no data	no data
Frank Czworka	Senior Vice President of Global Sales	2.8yrs	no data	no data

2.3yrs

Average Tenure

59yo

Average Age

Experienced Management: NVAX's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
John Jacobs	President	less than a year	no data	no data
David Mott	Independent Director	2.9yrs	US$380.56k	0.051% $ 315.8k
Richard Douglas	Independent Director	13.3yrs	US$382.56k	0.043% $ 268.6k
Margaret McGlynn	Independent Director	2.4yrs	US$369.17k	0.0044% $ 27.4k
Gregg Alton	Independent Director	2.6yrs	US$378.06k	0.0044% $ 27.4k
Rachel King	Independent Director	4.5yrs	US$368.54k	0.014% $ 88.3k
Richard Rodgers	Independent Director	less than a year	US$639.51k	no data
James Young	Independent Chairman of the Board	13.1yrs	US$561.55k	0.081% $ 505.3k

2.8yrs

Average Tenure

60yo

Average Age

Experienced Board: NVAX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Novavax Management

Management criteria checks 1/4

Key information

Recent management updates

High number of new directors

Novavax, Inc. Announces Chief Executive Officer Changes

Novavax, Inc. Appoints Richard J. Rodgers as Member of Its Audit Committee and as A Member of Its Compensation Committee

Novavax, Inc., Annual General Meeting, Jun 16, 2022

Recent updates

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

No longer forecast to breakeven

Forecast to breakeven in 2025

Novavax, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 16% to US$39.33

Consensus EPS estimates upgraded to US$4.96 loss, revenue downgraded

Consensus revenue estimates decrease by 25%

Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook

No longer forecast to breakeven

Price target increased by 23% to US$68.33

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Novavax, Inc. announced that it has received $6.75 million in funding from River Private Wealth

Novavax, Inc. Announces Chief Executive Officer Changes

Novavax, Inc. Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

Price target decreased to US$61.50

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Novavax, Inc. Appoints Richard J. Rodgers as Member of Its Audit Committee and as A Member of Its Compensation Committee

Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Approval in Canada for Use as a Primary Series in Adolescents

No longer forecast to breakeven

Novavax, Inc. Announces the World Health Organization Issue an Updated Emergency Use Listing (EUL) for Nuvaxovid(TM) (NVX-CoV2373) COVID-19

Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

Price target decreased to US$78.17

Consensus forecasts updated

Novavax, Inc. Announces Medicines and Healthcare Products Regulatory Agency Expands Conditional Marketing Authorization for Nuvaxovid™ COVID-19 Vaccine

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Novavax, Inc. Revises Revenue Guidance for the Year 2022

Novavax, Inc. to Report Q3, 2022 Results on Nov 08, 2022

U.S. FDA Grants Emergency Use Authorization for Novavax, Inc.'s COVID-19 Vaccine, Adjuvanted as a Booster for Adults

COVID-19 remains global health emergency - WHO

Novavax, Inc. Announces Positive Results from Phase 1/2 Clinical Trial of Its COVID-19-Influenza Combination (CIC) Vaccine Candidate

Novavax, Inc. Presents Data from the Phase 3 PREVENT-19 Trial and Study 307 (Lot Consistency) at the World Vaccine Congress Europe 2022

Forecast breakeven date pushed back to 2023

Novavax spikes ahead of presentations on COVID-19 vaccine portfolio

US Supreme Court declines to hear challenge of COVID vaccine mandate for health workers

Novavax makes 1M doses of its COVID-19 vaccine available for use in the UK

Forecast breakeven date pushed back to 2023

Price target decreased to US$106

Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17

Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax Covid-19 Vaccine as A Primary Series for Adults Aged 18 and Older

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as A Booster for Adults Aged 18 and Older

EU clears Novavax's COVID-19 shot for use as a booster dose in adults

Swissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older

Novavax Nuvaxovid COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older

Novavax wins EU backing for COVID-19 booster shot

Novavax, Inc. Nuvaxovid™ Covid-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17

Novavax: Finding Its Niche

Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17

Novavax, Inc. announces Nuvaxovid COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as First and Second Booster for Adults

Novavax COVID vaccine gets provisional approval in New Zealand as booster shot

Novavax, Inc. Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older

Price target decreased to US$126

Novavax Q2: Time To Turn Bullish After The Massive Collapse

Bearish: Analysts Just Cut Their Novavax, Inc. (NASDAQ:NVAX) Revenue and EPS estimates

Forecast breakeven date pushed back to 2023

Novavax, Inc. Is Revises Revenue Guidance for Full Year 2022

Price target decreased to US$126

Novavax, Inc. Initiates Phase 2b/3 Hummingbird Global Clinical Trial for the Novavax Covid-19 Vaccine in Children Aged Six Months Through 11 Years

Novavax COVID-19 shot is linked to rare cases of heart inflammation – EU agency

Novavax, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan

Novavax gets Japanese regulatory nod for use of its COVID vaccine in teens

Serum Institute of India supplies Novavax's COVID vaccine in US

U.S. FDA Grants Emergency Use Authorization for Novavax, Inc. COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over

Novavax to deliver 3.2M doses of COVID-19 vaccine to U.S.

Novavax, Inc. Announces European Commission Approves Expanded Conditional Marketing Authorization of Nuvaxovid™ (NVX-CoV2373) COVID-19 Vaccine in European Union for Adolescents Aged 12 Through 17

Novavax wins EU nod to use COVID-19 vaccine in adolescents

Novavax, Inc. Presents Data At FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants